Summary

“Look at how benefits and risks are allocated among different design options and pick a product architecture that minimizes risks and maximizes benefits.”

In this Let’s Talk Risk! conversation, Richard Matt shares a simple but uncomfortable observation: most organizations do risk “correctly” on paper, but too late to matter. By the time the DFMEA/PFMEA is polished, key architecture decisions are already locked, so risk management becomes cleanup, not guidance.

His most valuable takeaway is the shift upstream: start with the treatment plan, write down the expected benefits and plausible risks early, and iterate them as the design evolves. When benefits are made explicit, you stop treating risk as a single independent variable and start using benefit–risk as a practical decision engine for design tradeoffs.

Listen to the full 30-minute podcast or jump to a section of interest listed below.

Chapters

00:00 Welcome and Introduction

01:04 Risk focus in QMSR

04:50 Risk as an input to design

05:33 Why FMEA alone is not sufficient

10:33 Consider both benefits and risks early in design

20:43 Audience questions

24:30 Closing remarks

If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.

Suggested links:

LTR: Allison Komiyama on Rethinking Benefit-Risk in MedTech.

LTR: Benefit-Risk Evaluation of an AI/ML Enabled Device.

LTR: An Ideal Medical Device.

Key Takeaways

* Use benefit–risk early, not as an afterthought. Start at the treatment-plan/concept phase so benefit and harm shape architecture decisions before they’re hard to change.

* Make “benefit” explicit and usable. If you only optimize against harm, you can unintentionally degrade clinical value; benefit must be part of the design tradeoff logic from day one.

* FMEA is necessary, but often too late to drive architecture. Treat it as confirmation and refinement—not the first time risk influences design.

* Replace ad hoc early risk with a lightweight upstream method. A simple evolving list of benefits, risks, and the design choices they drove can outperform a “perfect” late-stage file.

* QMSR will expose weak integration between risk and design controls. The compliance work is not the hard part—the hard part is showing risk actually shaped the design.

Keywords

QMSR, ISO 13485, ISO 14971, design controls, risk-based thinking, DFMEA/PFMEA limits, hazards & hazardous situations, benefit–risk, early design inputs, architecture decisions, process validation (OQ/PQ), iterative development.

About Richard Matt

Richard Matt is Principal Consultant at Aspen Medical Risk Consulting, with over 30 years of experience in product development, quality engineering, and risk management. He specializes in innovative methods for benefit–risk assessment, FMEA, and integrated product development, helping medical device companies strengthen compliance and improve patient safety.

He is also the inventor of a patented “risk algebra” approach that enables clear, defensible comparisons of benefit and risk, a breakthrough with wide implications for devices, biologics, and combination products.

Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn.

Disclaimer

Information and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations.

Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe